NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $23.18 -0.52 (-2.19%) Closing price 08/13/2026 04:00 PM EasternExtended Trading$23.06 -0.11 (-0.50%) As of 06:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pacira BioSciences Stock (NASDAQ:PCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pacira BioSciences alerts:Sign Up Key Stats Today's Range$23.01▼$24.2950-Day Range$22.33▼$27.6252-Week Range$18.80▼$27.66Volume806,769 shsAverage Volume714,185 shsMarket Capitalization$923.95 millionP/E Ratio66.23Dividend YieldN/APrice Target$29.80Consensus RatingHold Company Overview Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain. In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control. The company has advanced clinical research in areas such as extended-release meloxicam formulations for soft tissue and orthopedic procedures, aiming to further expand its portfolio of non-opioid pain therapies. Pacira collaborates with healthcare providers and research partners to support clinical trials and to explore potential new indications for its proprietary technologies. Founded in 2006 and headquartered in Parsippany, New Jersey, Pacira BioSciences markets its products throughout the United States and in select international territories. The company emphasizes education and training for healthcare professionals to ensure the safe and effective use of its therapies. Pacira’s operations encompass regulatory affairs, medical affairs, and commercial functions, all dedicated to advancing patient-centered approaches to pain management.AI Generated. May Contain Errors. Read More Pacira BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScorePCRX MarketRank™: Pacira BioSciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 249th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialPacira BioSciences has a consensus price target of $29.80, representing about 28.6% upside from its current price of $23.18.Amount of Analyst CoveragePacira BioSciences has only been the subject of 4 research reports in the past 90 days.Read more about Pacira BioSciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth21.21% Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 21.21% in the coming year, from $1.98 to $2.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 66.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 66.23, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.68.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.33% of the float of Pacira BioSciences has been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 13.39, which indicates bearish sentiment.Change versus previous monthShort interest in Pacira BioSciences has recently increased by 3.57%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.81 News SentimentPacira BioSciences has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Pacira BioSciences this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 1 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $143,702.00 in company stock.Percentage Held by Insiders6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCRX Stock News HeadlinesHC Wainwright Cuts Earnings Estimates for Pacira BioSciencesAugust 14 at 1:28 AM | americanbankingnews.comQ4 EPS Estimate for Pacira BioSciences Increased by AnalystAugust 13 at 2:31 AM | americanbankingnews.comWall Street Preps for a 382 Trillion Dollar Financial Shift by 2027Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year before, as the smartest institutional money doubles down on blockchain infrastructure. This isn't speculative crypto trading. It's the payment rails and settlement systems moving money faster and cheaper. BlackRock, JPMorgan, and Fidelity are already accumulating the single digital asset positioned at the center of a $382 trillion shift in financial assets by April 2027.August 14 at 1:00 AM | Awesomely (Ad)Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?August 10, 2026 | finance.yahoo.comPacira BioSciences (NASDAQ:PCRX) Raised to "Strong-Buy" at Wall Street ZenAugust 8, 2026 | americanbankingnews.comPacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth PlatformAugust 8, 2026 | seekingalpha.comNeedham & Company LLC Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) StockAugust 7, 2026 | americanbankingnews.comRoyal Bank Of Canada Increases Pacira BioSciences (NASDAQ:PCRX) Price Target to $25.00August 7, 2026 | americanbankingnews.comSee More Headlines PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $25.88 at the beginning of 2026. Since then, PCRX stock has decreased by 10.4% and is now trading at $23.18. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) released its earnings results on Tuesday, August, 4th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.08. The company's revenue was up 6.2% compared to the same quarter last year. Read the conference call transcript. When did Pacira BioSciences IPO? Pacira BioSciences (PCRX) raised $64 million in an initial public offering (IPO) on Wednesday, February 2nd 2011. The company issued 4,250,000 shares at $14.00-$16.00 per share. Who are Pacira BioSciences' major shareholders? Top institutional investors of Pacira BioSciences include Bank of New York Mellon Corp (0.75%), Hennion & Walsh Asset Management Inc. (0.52%), Assenagon Asset Management S.A. (0.26%) and Wedge Capital Management L L P NC (0.24%). Insiders that own company stock include Jonathan Slonin, Daryl Gaugler, Frank D Lee, Shawn Cross, Kristen Williams, Lauren Riker, Mark Froimson and Marcelo Bigal. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/04/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 PCRX's financial health is in the Green zone, according to TradeSmith. PCRX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees720Year Founded2006Price Target and Rating Average Price Target for Pacira BioSciences$29.80 High Price Target$38.00 Low Price Target$25.00 Potential Upside/Downside+28.6%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.35 Trailing P/E Ratio66.23 Forward P/E Ratio11.71 P/E GrowthN/ANet Income$7.03 million Net Margins1.96% Pretax Margin2.37% Return on Equity9.68% Return on Assets5.30% Debt Debt-to-Equity Ratio0.54 Current Ratio5.04 Quick Ratio3.94 Sales & Book Value Annual Sales$726.41 million Price / Sales1.27 Cash Flow$3.78 per share Price / Cash Flow6.14 Book Value$16.86 per share Price / Book1.37Miscellaneous Outstanding Shares39,860,000Free Float37,311,000Market Cap$923.95 million OptionableOptionable Beta0.27 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PCRX) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
